Department and Clinic of Internal Diseases, Diabetology, and Nephrology, Metabolic Bone Diseases Unit, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 3-Maja 13/15 Street, 41-800 Zabrze, Katowice, Poland.
Department of Pediatrics, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Katowice, Poland.
Osteoporos Int. 2021 Oct;32(10):2043-2049. doi: 10.1007/s00198-021-05941-3. Epub 2021 Apr 5.
Human body height loss of 3-4 cm or more may be considered a simple indicator of increasing fracture risk, where the information is very similar to the results from fracture risk assessments by available online calculators, all of them based on a multiple variable approaches.
The aim of the study was to assess the relationship between body height loss (HL) and fracture risk in postmenopausal women from the Gliwice Osteoporosis (GO) Study.
The study sample included 1735 postmenopausal women, aged over 55 years and recruited at the Osteoporotic Outpatient Clinic. The mean age of the study participants was 68.15 ± 8.16 years. Fracture risk was established, using the fracture risk assessment tool (FRAX) (10-year probability of major and hip fractures), the Garvan calculator (any and hip fractures, 5 and 10 years) and the Polish (POL-RISK) algorithm, available at www. fracture - risk .pl (any fractures, 5 years). Bone densitometry at the femoral neck was performed, using a Prodigy device (Lunar, GE, USA). Body heights were measured before bone densitometry, using a wall stadiometer and compared with the maximum body heights, measured in early adulthood and reported by the study participants themselves.
In 199 women, the body heights, measured during the study, did not change in comparison to their corresponding values in early adulthood, while being decreased in the other 1536 women. The mean height loss (HL) in the whole study group was 3.95 ± 3.24 cm. That HL correlated significantly with the calculated fracture risk (the r range from 0.13 to 0.39, p < 0.0001). In general, regarding the patients with fracture risk close to the recommended therapeutic thresholds, HL was around 3-4 cm, except of the values from the FRAX calculator for major fractures, where the commonly used therapeutic threshold (20%) was related to HL of approximately 6.5 cm. In subjects with HL between 3.5 and 4 cm (n = 208), the FRAX value for major fractures was 6.83 ± 3.74.
Body height measurements, carried out to establish HL, provide an important information for clinical practice, where HL of 3-4 cm or more may be considered a simple indicator of increasing fracture risk.
人体身高损失 3-4 厘米或更多，可能被视为骨折风险增加的简单指标，这与现有在线计算器进行骨折风险评估的结果非常相似，所有这些都基于多变量方法。
本研究旨在评估绝经后妇女的身高损失（HL）与骨折风险之间的关系，该研究来自格利维采骨质疏松症（GO）研究。
研究样本包括 1735 名 55 岁以上的绝经后妇女，在骨质疏松症门诊招募。研究参与者的平均年龄为 68.15 ± 8.16 岁。使用骨折风险评估工具（FRAX）（10 年主要和髋部骨折概率）、Garvan 计算器（任何和髋部骨折、5 年和 10 年）和波兰（POL-RISK）算法确定骨折风险，该算法可在 www.fracture-risk.pl 上获得（任何骨折，5 年）。使用 Prodigy 设备（Lunar，GE，美国）在股骨颈处进行骨密度测定。使用壁式测高仪测量身高，与研究参与者自己报告的成年早期的最大身高进行比较。
在 199 名女性中，研究期间测量的身高与成年早期的身高没有变化，而在另外 1536 名女性中身高下降。整个研究组的平均身高损失（HL）为 3.95 ± 3.24 厘米。该 HL 与计算出的骨折风险显著相关（r 范围从 0.13 到 0.39，p < 0.0001）。一般来说，对于接近推荐治疗阈值的骨折风险患者，HL 约为 3-4 厘米，除了 FRAX 计算器对于主要骨折的风险值，其中常用的治疗阈值（20%）与大约 6.5 厘米的 HL 相关。在 HL 为 3.5 至 4 厘米之间的患者（n = 208）中，主要骨折的 FRAX 值为 6.83 ± 3.74。
为确定 HL 而进行的身高测量为临床实践提供了重要信息，其中 3-4 厘米或更多的 HL 可能被视为骨折风险增加的简单指标。
